Eris Lifesciences Limited — Q1 FY26 earnings call

Call held 5 Aug 2025

Management summary

ERIS delivered a strong bottom-line performance in Q1 FY26, driven by margin expansion in the core Domestic Branded Business and the successfully integrated Biocon portfolio. While consolidated revenue growth was tempered by the intentional ramp-down of Trade Generics and temporary insulin supply shortages, the company is pivoting toward high-margin segments like GLP-1 and European CDMO opportunities. Management remains committed to significant deleveraging, targeting a Net Debt/EBITDA ratio of 1.5x by the end of FY26.

Highlights

  • Consolidated Revenue reached ₹773 crores, representing a 7.4% YoY growth.

  • Consolidated PAT surged 41% YoY to ₹125 crores, up from ₹89 crores in Q1 last year.

  • Domestic Branded Business (DBF) grew 11% YoY to ₹702 crores with margins expanding to 37.2%.

  • Biocon segment operating margins improved significantly to 30% from 19% at the time of acquisition.

  • Net Debt stood at ₹2,300 crores, with a target to reduce this to ₹1,800 crores by fiscal year-end.

  • Strategic decision taken to ramp down the non-profitable Trade Generics business, which saw revenue drop to ₹3 crores from ₹13 crores.

  • Insulin business faced a ₹10 crore revenue hit due to drug product shortages, though drug substance (API) stockpiling is complete.

  • Confirmed CDMO contracts exceeding ₹100 crores per annum are in place for the international business starting next year.

Concerns

  • High Dependency on Single API Supplier for Insulin

Key financials

  1. Revenue ₹773 Cr +7.4%YoY
  2. EBITDA Margin 36%
  3. PAT ₹125 Cr +41%YoY
  4. EPS ₹9 +41%YoY
  5. Net Debt ₹2,300 Cr +4.5%QoQ

What they filed

Q1 FY27: revenue down 23.3%, net profit down 52.0% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue437 400 405 579 650 +49%315 −21%277 −32%444 −23%
EBITDA143 100 121 216 297 +108%77 −23%22 −82%120 −44%
Net profit28 2 30 100 150 +436%3 +50%-9 −130%48 −52%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • Domestic Branded Business (DBF)
    ₹702 Cr Revenue37.2% EBITDA Margin11% YoY Growth
  • Biocon Segment
    30% Operating Margin
  • International Business (Swiss Parenterals)
    ₹68 Cr Revenue₹22 Cr EBITDA
  • Trade Generics
    ₹3 Cr Revenue₹5 Cr EBITDA Loss

Guidance & targets

Debt

  • Net Debt Debt · FY26 · High confidence ₹1,800 crores
    we reaffirm our net debt guidance of INR 1,800 crores by the end of the year, which will bring us to a net debt to EBITDA of around 1.5x.

    — V. Krishnakumar, COO

Revenue

  • CDMO Confirmed Contracts Revenue · FY27 · High confidence ₹100 crores
    We have confirmed contracts of more than INR 100 crores revenue per annum, which are in various stages of execution... starting the next financial year.

    — V. Krishnakumar, COO

  • International Business Revenue Revenue · FY28-29 · Medium confidence ₹1,000 crores
    we have talked about that there is a good possibility of the international businesses going up to INR 1000 crores in FY28, ‘29.

    — Amit Bakshi, CMD

  • RHI Pen-Fill Market Opportunity Revenue · Steady state post-Novo exit · Medium confidence ₹200+ crores incremental
    We've called out earlier that this market opportunity is something where we can get an upside of INR 200 plus crore per annum on a steady state basis once all the stocks are exhausted.

    — V. Krishnakumar, COO

Other

  • Depreciation and Amortization Other · FY26 · High confidence ₹335 crores
    in Q4 we had guided that for FY26, the depreciation and amortization for the full year will be about INR 335 crores.

    — Kruti Raval, VP-M&A

Capacity

  • Export Injectable Capacity Capacity · next 1.5 to 2 years · Medium confidence 3x
    But once it comes up, Kunal, we are then preparing for a 3x capacity of what we are.

    — Amit Bakshi, CMD

Risks & concerns

  • High Dependency on Single API Supplier for Insulin

    high

    Dependency on Biocon for insulin API necessitated a ₹73 crore working capital investment to build a strategic stockpile.

    Management acknowledged

  • Insulin Drug Product (DP) Shortages

    medium

    Caused a ₹10 crore revenue loss in Q1; management expects situation to ease as the Bhopal facility ramps up in Q4.

    Management acknowledged

  • Regulatory Delay for Obesity Indication

    medium

    Permission for 3mg Liraglutide (Saxenda) is pending, delaying the entry into the high-growth obesity market.

    Both acknowledged

  • Capacity Constraints in Export Business

    medium

    Current lines are at capacity, limiting volume growth for the next 1.5-2 years until new units are commissioned.

    Management acknowledged

Areas of evasion (1)

  • Specific pricing strategy for generic Semaglutide (called it 'strategic in nature').

Q&A highlights

2 direct
Liraglutide (Saxenda) Ramp-up and Obesity Approval Partial
We haven't yet got our obesity Lira... We haven't got permission yet, so we are just waiting. There's little bit hiccup there.

Reveals a regulatory delay in a key growth driver (obesity indication) which led management to lower internal expectations for the brand this year.

Asked by Harith Ahamed

Insulin Shortage vs. Strategic Stockpiling Direct
It is the API which we have bulked up considering that our own facility will start soon. The problem which we kind of were talking about was more from the formulation point.

Clarifies the paradox of having a shortage while building inventory; the shortage is in finished product (DP) while the inventory build is in raw material (API) to ensure long-term self-sufficiency.

Asked by Bino Pathiparampil

Trade Generics Ramp-down Rationale Direct
We found even if we scale up to, say, four times where it is today, the margin will still be very scratchy... We just wanted to preserve ourselves to get to the core of the business.

Confirms a strategic shift away from low-margin volume to protect overall corporate profitability and focus management bandwidth.

Asked by Pragati Lunawat

2 min read 6 chapters

Detailed narrative

Core Domestic Business Outperforms Market

The Domestic Branded Business (DBF) remains the primary engine of growth, expanding 11% YoY to ₹702 crores. This outperformed the Indian Pharmaceutical Market (IPM) by 330 basis points. If adjusted for discontinued Fixed Dose Combinations (FDCs) and insulin shortages, the underlying segment growth was even stronger at 13-14%. Operating margins for this segment reached a robust 37.2%, demonstrating strong operating leverage even after adding 300 new Medical Representatives this year.

Biocon Integration and Margin Expansion

The Biocon segment continues to show significant value creation post-acquisition. Operating margins for this vertical have expanded to 30% in Q1 FY26, a substantial jump from the 19% margin recorded at the time of acquisition. Management expects further normalization as cartridge volumes stabilize and production eventually moves in-house to the Bhopal facility.

Strategic Pivot in International and CDMO

Eris is aggressively pivoting its international business (Swiss Parenterals) toward the 'Top of the Pyramid' by targeting regulated EU markets and marquee generic clients. The company has already secured confirmed CDMO contracts worth over ₹100 crores per annum. While current capacity constraints limit volume, a planned 3x capacity expansion over the next 2 years is intended to support a long-term goal of ₹1,000 crores in international revenue by FY28-29.

Insulin Supply Chain and Bhopal Commissioning

The company faced a ₹10 crore revenue headwind due to insulin drug product shortages in Q1. To mitigate future risks, Eris invested ₹73 crores in a strategic API stockpile, which impacted operating cash flow. Crucially, the Bhopal facility has now commenced manufacturing insulin vials, with cartridge production expected to follow in Q4. This move toward self-sufficiency is timed to capture the market vacancy left by Novo Nordisk's exit from the human insulin cartridge segment.

GLP-1 Pipeline and Market Formation

Management is highly optimistic about the GLP-1 (Semaglutide) opportunity, estimating the post-patent expiry market in India at ₹2,000-3,000 crores. Their recombinant Semaglutide candidate is on track to enter Phase-1 trials in Q4. While the current Liraglutide ramp-up has been slower than expected due to pending obesity approvals, Eris maintains its goal of being among the first generic players to launch Semaglutide in India.

Deleveraging and Financial Discipline

Despite net debt rising to ₹2,300 crores in Q1 due to capex and inventory building, management reaffirmed its year-end target of ₹1,800 crores. This deleveraging will be supported by strong internal accruals and the decision to exit the non-profitable Trade Generics business. The company reported a 41% YoY growth in PAT, signaling that the earnings per share (EPS) acceleration phase has commenced as per prior guidance.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls